In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Roivant Sciences Ltd (NASDAQ: ROIV) closed at $16.99 in the last session, up 3.60% from day before closing price of $16.4. In other words, the price has increased by $3.60 from its previous closing price. On the day, 9.97 million shares were traded. ROIV stock price reached its highest trading level at $17.125 during the session, while it also had its lowest trading level at $16.41.
Ratios:
We take a closer look at ROIV’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 40.54 and its Current Ratio is at 40.54. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Citigroup on September 02, 2025, initiated with a Buy rating and assigned the stock a target price of $16.
On February 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $17.Wolfe Research initiated its Outperform rating on February 15, 2024, with a $17 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 15 ’25 when Venker Eric bought 414,683 shares for $16.93 per share.
Venker Eric sold 104,940 shares of ROIV for $1,710,522 on Oct 09 ’25. The President & Immunovant CEO now owns 1,504,959 shares after completing the transaction at $16.30 per share. On Oct 13 ’25, another insider, Venker Eric, who serves as the President & Immunovant CEO of the company, sold 20,727 shares for $16.25 each. As a result, the insider received 336,814 and left with 1,504,959 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ROIV now has a Market Capitalization of 11602160640 and an Enterprise Value of 7668975616. For the stock, the TTM Price-to-Sale (P/S) ratio is 499.45 while its Price-to-Book (P/B) ratio in mrq is 2.67. Its current Enterprise Value per Revenue stands at 330.09 whereas that against EBITDA is -6.679.
Stock Price History:
The Beta on a monthly basis for ROIV is 1.19, which has changed by 0.37699413 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, ROIV has reached a high of $16.79, while it has fallen to a 52-week low of $8.73. The 50-Day Moving Average of the stock is 23.69%, while the 200-Day Moving Average is calculated to be 46.07%.
Shares Statistics:
According to the various share statistics, ROIV traded on average about 6.50M shares per day over the past 3-months and 6435900 shares per day over the past 10 days. A total of 682.23M shares are outstanding, with a floating share count of 415.36M. Insiders hold about 39.18% of the company’s shares, while institutions hold 64.11% stake in the company. Shares short for ROIV as of 1759190400 were 27966982 with a Short Ratio of 4.31, compared to 1756425600 on 39048414. Therefore, it implies a Short% of Shares Outstanding of 27966982 and a Short% of Float of 5.4899998.
Earnings Estimates
The stock of Roivant Sciences Ltd (ROIV) is currently being evaluated by 4.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.25 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$0.95 and -$1.56 for the fiscal current year, implying an average EPS of -$1.16. EPS for the following year is -$1.3, with 4.0 analysts recommending between -$1.02 and -$1.82.
Revenue Estimates
According to 7 analysts,. The current quarter’s revenue is expected to be $6.92M. It ranges from a high estimate of $15M to a low estimate of $1.78M. As of. The current estimate, Roivant Sciences Ltd’s year-ago sales were $29.26MFor the next quarter, 7 analysts are estimating revenue of $7.1M. There is a high estimate of $15M for the next quarter, whereas the lowest estimate is $1.78M.
A total of 9 analysts have provided revenue estimates for ROIV’s current fiscal year. The highest revenue estimate was $47.2M, while the lowest revenue estimate was $2.17M, resulting in an average revenue estimate of $21.43M. In the same quarter a year ago, actual revenue was $29.05MBased on 9 analysts’ estimates, the company’s revenue will be $169.51M in the next fiscal year. The high estimate is $567.77M and the low estimate is $7.87M.
